According to recent studies, puerarin could ameliorate glucose content and lipid metabolic disorders in the liver by regulating the adenosine 5′-monophosphate-activated protein kinase pathway and downregulating the gene expression levels of acetoacetyl coenzyme A (Acetyl-CoA) carboxylase (ACC1), fatty acid synthase (FASN), stearoyl-coenzyme A desaturase 1 (SCD1), and sterol regulatory element binding transcription factor-1c (SREBP-1c) (26). The gene discussed is FASN; the disease is medical procedure.